Risk factors for tube exposure following Baerveldt glaucoma implantation and overlying tissue thickness assessed by anterior segment optical coherence tomography
Japanese Journal of Ophthalmology · 2026
DOI: 10.1007/s10384-026-01366-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Ophthalmology, 2026. Verfasst von Natsumi Murata und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. Hauptthemen laut MEDLINE: Tomography, Optical Coherence, Glaucoma Drainage Implants, Intraocular Pressure, Anterior Eye Segment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kumamoto University.
Abstract (Originalsprache)
Purpose
We identified clinical factors associated with tube exposure following Baerveldt glaucoma implantation (BGI) and used anterior segment optical coherence tomography (AS-OCT) to assess postoperative tissue thickness over the tube. Study design Retrospective, single-center cohort study.
Methods
In this single-center retrospective cohort study, 405 eyes underwent BGI (BG101-350) with preserved scleral patch grafts between October 2014 and December 2022. Tube exposure was documented through clinical records and slit-lamp examination. Risk factors were evaluated using Firth’s penalized logistic regression. Overlying tissue thickness at 1 year postoperatively was measured via AS-OCT, and its association with clinical variables was analyzed using linear regression.
Results
The mean follow-up was 630.7 days, and tube exposure occurred in 12 eyes (2.96%). Neovascular glaucoma (NVG) (odds ratio [OR] 5.03, p = 0.033) and anterior chamber (AC) tube insertion (OR 6.07, p = 0.017) were independently associated with exposure. Overlying tissue was significantly thinner with AC insertion compared with ciliary sulcus or pars plana placement (Kruskal–Wallis with Bonferroni-adjusted Dunn’s tests; AC vs sulcus, p = 0.039; AC vs pars plana, p < 0.001). Among eyes with AC insertion, prior micropulse transscleral cyclophotocoagulation (MP-CPC) was associated with greater tissue thickness (estimate 0.173; p = 0.032).
Conclusion
AC insertion and NVG were associated with an increased risk of tube exposure after BGI. AS-OCT revealed thinner tissue over AC-placed tubes, providing a structural basis for this risk. Avoiding AC insertion may reduce exposure; the observed association between prior MP-CPC and thicker tissue requires prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
- Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. sachikojima@kumamoto-u.ac.jp.
Förderung
- Kumamoto University
Zitieren
APA
Murata, N., Kojima, S., Takihara, Y., Takahashi, E., Nakashima, K. I., & Inoue, T. (2026). Risk factors for tube exposure following Baerveldt glaucoma implantation and overlying tissue thickness assessed by anterior segment optical coherence tomography. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-026-01366-9
Vancouver
Murata N, Kojima S, Takihara Y, Takahashi E, Nakashima KI, Inoue T. Risk factors for tube exposure following Baerveldt glaucoma implantation and overlying tissue thickness assessed by anterior segment optical coherence tomography. Japanese Journal of Ophthalmology. 2026. doi:10.1007/s10384-026-01366-9
BibTeX
@article{Murata2026,
author = {Murata, Natsumi and Kojima, Sachi and Takihara, Yuji and Takahashi, Eri and Nakashima, Kei-Ichi and Inoue, Toshihiro},
title = {Risk factors for tube exposure following Baerveldt glaucoma implantation and overlying tissue thickness assessed by anterior segment optical coherence tomography},
journal = {Japanese Journal of Ophthalmology},
year = {2026},
doi = {10.1007/s10384-026-01366-9}
}
EUVIMED